Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120782 · ClinicalTrials.gov registry record · NA
Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types
A NA study of Astigmatism, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT01120782: Completed NA study of Astigmatism, sponsored by Johnson & Johnson Vision Care.
NCT01120782 is a NA study of Astigmatism that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 45 participants, below the 105-participant average among 31 other Astigmatism trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120782, a NA study of Astigmatism, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether the prescription determined for a new daily disposable toric contact lens will be a good match to a prescription determined for an existing brand of lens.
Primary Outcome
Number of subjects whose prescription is the same for the two lenses tested.
Conditions Studied
Interventions
- DEVICE etafilcon A toric contact lens with new wetting agent
- DEVICE etafilcon A toric contact lens
Study Locations (2)
Florida
- - Jacksonville
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2010-02-01 |
| Phase | NA |
What the finished NCT01120782 record still lists
NCT01120782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 105-participant average among 31 other Astigmatism trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Astigmatism appearing as the primary indexed condition, and to 2 interventions - of which etafilcon A toric contact lens with new wetting agent is the first listed.
NCT01120782 reports a single indexed study location in Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01120782 about?
NCT01120782 is a clinical study titled "Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types". The purpose of this study is to determine whether the prescription determined for a new daily disposable toric contact lens will be a good match to a prescription determined for an existing brand of lens.
What is the current status of trial NCT01120782?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2010-02-01. Estimated completion is 2010-02-01.
What conditions does trial NCT01120782 study?
This clinical trial studies the following conditions: Astigmatism.
What interventions are being tested in trial NCT01120782?
The interventions under investigation include: etafilcon A toric contact lens with new wetting agent (DEVICE), etafilcon A toric contact lens (DEVICE).
Who is sponsoring clinical trial NCT01120782?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01120782 being conducted?
This trial has 2 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astigmatism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01120782's enrollment target sits among peer trials
45 23rd of 31 higher than 9 of 31 other Astigmatism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Astigmatism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery
RECRUITING · NA
-
A Three-Phase Contralateral Comparison of Ray-Tracing Guided LASIK Versus Three Other Refractive Surgery Platforms to Correct Myopia or Myopia With Astigmatism
RECRUITING · NA
-
Contoura With Phorcides Compared to Wavefront Optimized LASIK
RECRUITING · NA
-
Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction
ACTIVE NOT RECRUITING · NA
-
LASIK iDesign vs SMILE
ACTIVE NOT RECRUITING · NA
-
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI